parent conditions

Breast Ductal Carcinoma

Invasive Breast Carcinoma

child conditions

Invasive Ductal Carcinoma, Not Otherwise Specified

Acinic Cell Breast Carcinoma

Medullary Breast Carcinoma

Tubular Breast Carcinoma

Secretory Breast Carcinoma

Lipid-Rich Breast Carcinoma

Invasive Apocrine Breast Carcinoma

Mucinous Breast Carcinoma

synonym

Breast invasive ductal carcinoma (IDC)

A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

193 sites for NCT04975308

ER Positive, +1 more biomarker

Breast Carcinoma

abemaciclib, +1 more drug

hormone therapy, +1 more type

A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)

90 sites for NCT04961996

ER Positive, +1 more biomarker

Breast Carcinoma

giredestrant, +1 more drug

hormone therapy

Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)

267 sites for NCT04784715

ERBB2 Amplification, +1 more biomarker

Breast Carcinoma

fam-trastuzumab deruxtecan, +2 more drugs

targeted therapy

Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer

144 sites for NCT05113251

ERBB2 Amplification, +1 more biomarker

Breast Carcinoma

fam-trastuzumab deruxtecan, +3 more drugs

chemotherapy, +1 more type

A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)

127 sites for NCT05104866

ER Positive, +2 more biomarkers

Breast Carcinoma

datopotamab deruxtecan

targeted therapy

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)

90 sites for NCT04895358

ER Positive, +2 more biomarkers

Breast Carcinoma

capecitabine, +4 more drugs

chemotherapy, +1 more type

olaparib

BRCA1 Loss, +3 more biomarkers

Breast Carcinoma

Early stage, +1 more state

Adjuvant

olaparib

targeted therapy

abemaciclib + (aromatase inhibitor or tamoxifen)

ER Positive, +1 more biomarker

Breast Carcinoma

Early stage, +2 more states

Adjuvant

abemaciclib, +2 more drugs

hormone therapy, +1 more type

pembrolizumab + chemotherapy

ER Negative, +2 more biomarkers

Breast Carcinoma

Early stage, +1 more state

Adjuvant, +1 more context

chemotherapy, +1 more drug

chemotherapy, +1 more type

margetuximab + chemotherapy

ERBB2 Amplification, +1 more biomarker

Breast Carcinoma

Metastatic

Subsequent line

chemotherapy, +1 more drug

chemotherapy, +1 more type

pembrolizumab + chemotherapy

PD-L1 Expression (CPS >= 10)

Breast Carcinoma

Locally recurrent, +2 more states

chemotherapy, +1 more drug

chemotherapy, +1 more type

pertuzumab/trastuzumab/hyaluronidase + chemotherapy

ERBB2 Amplification, +1 more biomarker

Breast Carcinoma

Early stage, +1 more state

Neoadjuvant

chemotherapy, +1 more drug

chemotherapy, +1 more type